PATENT CLAIM ANALYSIS

Application Number: 15975296
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["548", "255000"]

Abstract:
Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Claim (Index 35):
A compound of Formula III: and pharmaceutically acceptable salts and isomers thereof, wherein in Formula III:\n X 1  is CH or N; \n X 13  is (CH 2 ) 1-5  wherein at least one CH 2  is optionally replaced by aryl; \n R 2  is selected from the group consisting of H, COOH or CH 2 \u2014COOH; \n R 11  is selected from the group consisting of alkyne, N 3 , NO 2 , (CH 2 ) 1-10 \u2014R 12  wherein at least one CH 2  is optionally replaced by at least one of CONH, aryl or heteroaryl; and \n R 12  is selected from the group consisting of N 3 , alkyne, protecting group, halo and radioisotope; \n or\n a compound of Formula IV: \n and pharmaceutically acceptable salts and isomers thereof, wherein in Formula IV:\n X 1  is CH or N; \n X 14  is selected from the group consisting of: C(O) and heteroaryl, wherein at least one H of the heteroaryl is substituted with NO 2 ; \n X 15  is selected from the group consisting of: a bond, NH, CH 2 , aryl, heteroaryl, cycloalkyl and heterocycloalkyl; \n X 16  is at least one selected from the group consisting of: a bond, aryl, heteroaryl, (CH 2 ) 1-25 , wherein at least one CH 2  of (CH 2 ) 1-12  is optionally replaced with heteroaryl, aryl, CONH, and \u2014O\u2014; and \n R 13  is selected from the group consisting of H, NO 2 , N 3 , alkyne, protecting group, halo and radioisotope; \n or\n a compound of Formula V: \n and pharmaceutically acceptable salts and isomers thereof, wherein in Formula V:\n X 1  is CH or N; \n X 17  is selected from the group consisting of: N and CH; \n X 18  is selected from the group consisting of: (CH 2 ) 1-10  wherein at least one CH 2  of (CH 2 ) 1-10  is optionally replaced by NH, aryl, heteroaryl and wherein at least one H is optionally substituted with NO 2 ; and \n R 14  is selected from the group consisting of O and S; and \n R 15  is selected from the group consisting of N 3 , alkyne, protecting group, halo and radioisotope; \n or\n a compound of Formula VI: \n and pharmaceutically acceptable salts and isomers thereof, wherein in Formula VI:\n X 1  is CH or N; \n X 19  is selected from the group consisting of: H, NO 2 , (CH 2 ) 1-10 \u2014R 16  wherein at least one CH 2  of (CH 2 ) 1-10  is optionally replaced by CONH, aryl, heteroaryl; \n X 20  is selected from the group consisting of: H, NO 2 , (CH 2 ) 1-10 \u2014R 16  wherein at least one CH 2  of (CH 2 ) 1-10  is optionally replaced by CONH, aryl, heteroaryl; \n X 21  is selected from the group consisting of (CH 2 ) 1-3  wherein at least one CH 2  of (CH 2 ) 1-3  is optionally replaced by heteroaryl, and \n R 16  is selected from the group consisting of N 3 , alkyne, protecting group, halo and radioisotope; \n or\n a compound of Formula VII: \n and pharmaceutically acceptable salts and isomers thereof, wherein in Formula VII:\n X 1  is CH or N; \n X 2  is CH or N; \n X 22  is a protecting group; and \n X 23  is (CH 2 ) 1-10 \u2014NH 2  wherein at least one CH 2  of (CH 2 ) 1-10  is optionally replaced by at least one selected from the group consisting of S, O, NH, CONH, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; \n or\n a compound of Formula VIII: \n and pharmaceutically acceptable salts and isomers thereof, wherein in Formula VIII:\n X 1  is CH or N; \n X 24  is selected from the group consisting of (CH 2 ) 1-6  wherein at least one CH 2  of (CH 2 ) 1-6  is optionally replaced by at least one selected from the group consisting of NH, O, S; \n X 25  is N or CH; \n X 26  is NH or CH 2 ; \n X 27  is selected from the group consisting of H, NO 2 , (CH 2 ) 1-10 \u2014R 16  wherein at least one CH 2  of (CH 2 ) 1-10  is optionally replaced by O, CONH, aryl, heteroaryl; and \n R 16  is selected from the group consisting of N 3 , alkyne, protecting group, halo and radioisotope.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 93.0
- Lexical Diversity: 1.71429
- Patent Class: 548.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14917127', '12862955', '12099135', '14152864', '15492933']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7512147613555153
- 35 USC 102 Novelty (BERT): 0.6016087183306935
- Combined Prediction Score: 0.7362541570530332
- Mean Citation Score: 364.583886
- Max Citation Score: 519.5915
- Similarity Product: 475.8911872618795

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test